Literature DB >> 11561810

Molecular epidemiology of extended-spectrum beta-lactamases from Klebsiella pneumoniae strains isolated in Zagreb, Croatia.

B Bedenić1, C C Randegger, E Stobberingh, H Hächler.   

Abstract

In order to assess the molecular epidemiology of 40 previously identified extended-spectrum beta-lactamase (ESBL)-producing clinical isolates of Klebsiella pneumoniae, gene sequencing was performed. While the previous examination of these isolates revealed one TEM producer, the sequencing procedure performed in this study identified 13 additional TEM producers, and all of the sequenced genes reflected production of nonESBL TEM-1. All 38 suspected SHV producers were confirmed to be carriers of blaSHV-ESBL genes using the PCR/Nhel test and sequencing. Among them, types SHV-2, SHV-5, and SHV-12 were found in 20, 10, and 7 isolates, respectively, and SHV-2a was identified in 1. SHV-5 and SHV-12 conferred higher resistance to ceftazidime and cefepime, while SHV-2 and SHV-2a raised the minimum inhibitory concentrations of cefotaxime and cefpirome. Fourth-generation cephalosporins were found to be more active against the isolates than third-generation cephalosporins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561810     DOI: 10.1007/pl00011293

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

1.  Epidemiology of extended-spectrum beta-lactamases in Sofia, Bulgaria.

Authors:  G A Jacoby; R Vacheva-Dobrevsky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-29       Impact factor: 3.267

2.  Occurrence and regional distribution of SHV-type extended-spectrum beta-lactamases in Hungary.

Authors:  A Tóth; M Gacs; K Márialigeti; G Cech; M Füzi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-04       Impact factor: 3.267

3.  Characterization of the extended-spectrum β-lactamases and determination of the virulence factors of uropathogenic Escherichia coli strains isolated from children.

Authors:  Branka Bedenić; Jasmina Vraneš; Sabine Hofmann-Thiel; Marija Tonkić; Anita Novak; Viljemka Bučević-Popovic; Harald Hoffmann
Journal:  Wien Klin Wochenschr       Date:  2012-08-16       Impact factor: 1.704

Review 4.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

5.  Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases.

Authors:  David L Paterson; Kristine M Hujer; Andrea M Hujer; Bethany Yeiser; Michael D Bonomo; Louis B Rice; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 6.  Mechanisms of Resistance in Gram-Negative Urinary Pathogens: From Country-Specific Molecular Insights to Global Clinical Relevance.

Authors:  Branka Bedenić; Tomislav Meštrović
Journal:  Diagnostics (Basel)       Date:  2021-04-28

7.  Relationship between lactobacilli and opportunistic bacterial pathogens associated with vaginitis.

Authors:  Mohammad Sabri A Razzak; Alaa H Al-Charrakh; Bara Hamid Al-Greitty
Journal:  N Am J Med Sci       Date:  2011-04

8.  Distribution of ExPEC Virulence Factors, bla CTX-M, fosA3, and mcr-1 in Escherichia coli Isolated From Commercialized Chicken Carcasses.

Authors:  Paula Signolfi Cyoia; Vanessa Lumi Koga; Erick Kenji Nishio; Sébastien Houle; Charles M Dozois; Kelly Cristina Tagliari de Brito; Benito Guimarães de Brito; Gerson Nakazato; Renata Katsuko Takayama Kobayashi
Journal:  Front Microbiol       Date:  2019-01-14       Impact factor: 5.640

9.  Comparison of Antibiotic Resistance and Virulence Factors among Escherichia coli Isolated from Conventional and Free-Range Poultry.

Authors:  Vanessa L Koga; Sara Scandorieiro; Eliana C Vespero; Alexandre Oba; Benito G de Brito; Kelly C T de Brito; Gerson Nakazato; Renata K T Kobayashi
Journal:  Biomed Res Int       Date:  2015-10-22       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.